180 related articles for article (PubMed ID: 2324959)
1. In vitro dissolution and in vivo bioavailability of commercial levothyroxine sodium tablets in the hypothyroid dog model.
Wood RW; Martis L; Gillum AW; Roseman TJ; Lin L; Bernardo P
J Pharm Sci; 1990 Feb; 79(2):124-7. PubMed ID: 2324959
[TBL] [Abstract][Full Text] [Related]
2. Comparative bioavailability of two oral L-thyroxine formulations after multiple dose administration in patients with hypothyroidism and its relation with therapeutic endpoints and dissolution profiles.
Vaisman M; Spina LD; Eksterman LF; dos Santos MJ; Lima JS; Volpato NM; da Silva RL; de Brito AP; Noël F
Arzneimittelforschung; 2001; 51(3):246-52. PubMed ID: 11304941
[TBL] [Abstract][Full Text] [Related]
3. Multiple level C in vitro/in vivo correlation of dissolution profiles of two L-thyroxine tablets with pharmacokinetics data obtained from patients treated for hypothyroidism.
Volpato NM; Silva RL; Brito AP; Gonçalves JC; Vaisman M; Noël F
Eur J Pharm Sci; 2004 Apr; 21(5):655-60. PubMed ID: 15066666
[TBL] [Abstract][Full Text] [Related]
4. Are multisource levothyroxine sodium tablets marketed in Egypt interchangeable?
Abou-Taleb BA; Bondok M; Nounou MI; Khalafallah N; Khalil S
Ann Endocrinol (Paris); 2018 Feb; 79(1):23-29. PubMed ID: 29289332
[TBL] [Abstract][Full Text] [Related]
5. Tablet formulation of levothyroxine is absorbed less well than powdered levothyroxine.
Yamamoto T
Thyroid; 2003 Dec; 13(12):1177-81. PubMed ID: 14751040
[TBL] [Abstract][Full Text] [Related]
6. In vivo/in vitro correlations for four differently dissolving ketorolac tablets.
Gordon MS; Chowhan Z
Biopharm Drug Dispos; 1996 Aug; 17(6):481-92. PubMed ID: 8866039
[TBL] [Abstract][Full Text] [Related]
7. A study in normal human volunteers to compare the rate and extent of levothyroxine absorption from Synthroid and Levoxine.
Berg JA; Mayor GH
J Clin Pharmacol; 1992 Dec; 32(12):1135-40. PubMed ID: 1487553
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study.
Di Girolamo G; Keller GA; de Los Santos AR; Schere D; Gonzalez CD
Clin Ther; 2008 Nov; 30(11):2015-23. PubMed ID: 19108789
[TBL] [Abstract][Full Text] [Related]
9. Effect of batch age on potency and dissolution of levothyroxine sodium tablets: impact of BP and USP monograph differences on dissolution results.
Abou-Taleb BA; Nounou MI; Khalafallah N; Khalil S
Drug Dev Ind Pharm; 2018 Nov; 44(11):1762-1769. PubMed ID: 29973090
[TBL] [Abstract][Full Text] [Related]
10. Correlation between in vitro and in vivo parameters of commercial paracetamol tablets.
Babalola CP; Oladimeji FA; Femi-Oyewo MN
Afr J Med Med Sci; 2001 Dec; 30(4):275-80. PubMed ID: 14510103
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability of ciprofloxacin tablets in humans and its correlation with the dissolution rates.
Khan MK; Khan MF; Khan H; Mustafa G
Pak J Pharm Sci; 2009 Jul; 22(3):329-34. PubMed ID: 19553184
[TBL] [Abstract][Full Text] [Related]
12. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans.
Fish LH; Schwartz HL; Cavanaugh J; Steffes MW; Bantle JP; Oppenheimer JH
N Engl J Med; 1987 Mar; 316(13):764-70. PubMed ID: 3821822
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo characteristics of some commercial phenobarbital tablets.
Sylvestri MF; Ueda CT
Int J Clin Pharmacol Biopharm; 1979 Dec; 17(12):492-7. PubMed ID: 528095
[TBL] [Abstract][Full Text] [Related]
14. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
15. Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers.
Leggio GM; Incognito T; Privitera G; Marano MR; Drago F
J Endocrinol Invest; 2006 Dec; 29(11):RC35-8. PubMed ID: 17259789
[TBL] [Abstract][Full Text] [Related]
16. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
[TBL] [Abstract][Full Text] [Related]
17. An investigation into the influence of experimental conditions on in vitro drug release from immediate-release tablets of levothyroxine sodium and its relation to oral bioavailability.
Kocic I; Homsek I; Dacevic M; Parojcic J; Miljkovic B
AAPS PharmSciTech; 2011 Sep; 12(3):938-48. PubMed ID: 21748540
[TBL] [Abstract][Full Text] [Related]
18. A bioequivalence study of levothyroxine tablets versus an oral levothyroxine solution in healthy volunteers.
Yannovits N; Zintzaras E; Pouli A; Koukoulis G; Lyberi S; Savari E; Potamianos S; Triposkiadis F; Stefanidis I; Zartaloudis E; Benakis A
Eur J Drug Metab Pharmacokinet; 2006; 31(2):73-8. PubMed ID: 16898074
[TBL] [Abstract][Full Text] [Related]
19. Comparative bioavailability and in vitro characterization of two brands of diclofenac sodium enteric-coated tablets.
el-Sayed Y; Suleiman MS; Hasan M; Najib N; Muti H; Abdulhameed M
Int J Clin Pharmacol Ther Toxicol; 1988 Oct; 26(10):487-91. PubMed ID: 3235214
[TBL] [Abstract][Full Text] [Related]
20. Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
Metzmann K; Schnell D; Jungnik A; Ring A; Theodor R; Hohl K; Meinicke T; Friedrich C
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):549-63. PubMed ID: 24755124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
